By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German chemical proteomics firm Kinaxo Biotechnologies today announced a collaboration with AstraZeneca in support of one of its oncology programs.

Under the terms of the deal, Kinaxo will use it mass spectrometry-based technologies to quantitatively analyze post-translational modifications in proteins on a proteome-wide scale, it said in a statement. Information from the analyses is anticipated to provide insight into the cellular functions of potential drug targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.